Cancer Ovaries Clinical Trial
Official title:
A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
The purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread.
This is an open-label, Phase 1b dose escalation and expansion study of OMP-305B83 plus
paclitaxel designed to evaluate the safety, efficacy and pharmacokinetics of OMP-305B83 in
combination with paclitaxel in patients with platinum resistant ovarian, primary peritoneal
or fallopian tube cancer. This study consists of a screening period, a treatment period and a
post-treatment follow up period in which patients will be followed for survival for
approximately 12 months. Patients will be enrolled in two stages: a dose-escalation stage and
an expansion phase.
Approximately 30 patients will be enrolled in this study at approximately 5 study centers in
the United States (U.S)..
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05154474 -
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
|
||
| Recruiting |
NCT04258813 -
Onco-primary Care Networking to Support TEAM-based Care
|
N/A | |
| Active, not recruiting |
NCT03936075 -
Guided Imagery & Music in Cancer
|
N/A |